European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update

Rouprêt, Morgan; Babjuk, Marko; Burger, Maximilian; Čapoun, Otakar; Cohen, Daniel L.; Compérat, Éva; Cowan, Nigel C.; Domínguez-Escrig, José; Gontero, Paolo; Mostafid, Hugh; Palou, Joan; Peyronnet, B.; Seisen, Thomas; Soukup, Viktor; Sylvester, Richard; Rhijn, Bas W.G. van; Zigeuner, Richard; Shariat, Shahrokh F.

doi:10.1016/j.eururo.2020.05.042

Cited by 675 publications

(855 citation statements)

References 203 publications

Supporting

Mentioning

831

Contrasting

Unclassified

Order By: Relevance

“…In this setting, biomarkers such as C-reactive protein (CRP), lymphocyte-monocyte ratio and platelet-lymphocyte ratio have been investigated. Recently, NLR has emerged as a prognostic factor in upper urinary tract tumours [30] and other nonurological malignancies. The use of the NLR as a predictive tool is derived from studies using chemotherapy in oesophageal, gastric and colorectal cancers.…”

Section: Annals Of Oncologymentioning

confidence: 99%

EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees

et al. 2019

View full text Add to dashboard Cite

These consensus statements were developed by the European Association of Urology (EAU) and the European Society for Medical Oncology (ESMO) and are published simultaneously in European Urology and Annals of Oncology. Background: Although guidelines exist for advanced and variant bladder cancer management, evidence is limited/conflicting in some areas and the optimal approach remains controversial. Objective: To bring together a large multidisciplinary group of experts to develop consensus statements on controversial topics in bladder cancer management. Design: A steering committee compiled proposed statements regarding advanced and variant bladder cancer management which were assessed by 113 experts in a Delphi survey. Statements not reaching consensus were reviewed; those prioritised were revised by a panel of 45 experts before voting during a consensus conference. Setting: Online Delphi survey and consensus conference. Participants: The European Association of Urology (EAU), the European Society for Medical Oncology (ESMO), experts in bladder cancer management.

show abstract

Section: Annals Of Oncologymentioning

confidence: 99%

EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The treatment regimen included 6-weekly instillations of UGN-101 instilled via percutaneous nephrostomy tube (2) or ureteral catheter and performed without anesthesia in most patients. Two patients received twice-weekly instillations.…”

Section: Ugn-101 Administrationmentioning

confidence: 99%

“…Upper tract urothelial cancer (UTUC) is a rare malignancy and difficult to study in a randomized controlled setting [1]. Treatment guidelines are based mainly on retrospective series and expert opinion rather than strong (grade A) evidence [2]. Current practice is guided primarily by the clinical stage and histologic grade of the cancer.…”

Section: Introductionmentioning

confidence: 99%

“…Current practice is guided primarily by the clinical stage and histologic grade of the cancer. The European Association of Urology guidelines incorporate individual risk factors including location (ureter vs. renal pelvis) and extent of disease, tumor size, cytology, imaging, and previous history of urologic cancers [2]. Although these guidelines assist the clinical decision-making process of practicing urologists, when possible, the gold standard treatment for high-risk UTUC remains radical nephroureterectomy (NU) [3,4].…”

Section: Introductionmentioning

confidence: 99%

“…Intracavitary, topical therapy (Bacillus Calmette-Guerin (BCG), interferon with BCG, thiotepa, Mitomycin C, and epirubicin) in aqueous formulation is infrequently given as an adjunct to endoscopic treatment for residual disease or for prophylaxis in non-metastatic stage Ta and T1 UTUC [2,7]. Topical therapy can also be used for carcinoma in situ (CIS).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Thermo Reversible Hydrogel Based Delivery of Mitomycin C (UGN-101) for Treatment of Upper Tract Urothelial Carcinoma (UTUC)

Kleinmann

Wirth

Lin

et al. 2019

BLC

View full text Add to dashboard Cite

Background: There is an unmet need for an effective local treatment of upper tract urothelial carcinoma (UTUC). Drug delivery to the pyelocaliceal system and pursuant efficacy of intracavitary therapy is limited by urine production that washes the drug away, shortening dwell time and direct contact with the urothelium. Successful endoscopic management is often dictated by lesion size, grade, and focality. A thermo-reversible hydrogel formulation of Mitomycin C (UGN-101, formerly MitoGel) was developed and has demonstrated the safety and feasibility of increased time of the drug in the pyelocaliceal system resulting in chemoablation of tumors. Objectives: To examine the efficacy and safety of UGN-101 used for chemoablation of UTUC. Methods: There were 22 patients approved for compassionate use treatment at 14 institutions. Six-weekly instillations of UGN-101 were administered via ureteral catheter or percutaneous nephrostomy. Ureteroscopy was performed 2-6 weeks following treatment completion for response determination. Adverse events were recorded throughout treatment. Patients were followed up according to the standard of care of each center.

show abstract

Urothelial Cancer

Côté¹,

Burgess²,

McHaffie³

et al. 2022

Holland‐Frei Cancer Medicine

View full text Add to dashboard Cite

Overview Urothelial malignancy is one of the commonest cancers in Western society and involves the bladder, urethra, ureters, and renal calyces. It is associated with smoking, industrial dyes, schistosomiasis, radiation exposure, and certain geographical locations. Well‐defined molecular prognosticators and predictors have been identified, and in combination with improved staging techniques, have led to improved outcomes. Patients with nonmuscle invasive urothelial malignancy are best managed by surgical resection, often in combination with intravesical immunotherapy or chemotherapy. Muscle invasive disease is best managed by neoadjuvant cisplatin‐based chemotherapy followed by cystectomy; less robust patients are often effectively treated by chemoradiation. Patients with metastatic disease achieve response rates of up to 70% with MVAC or GC combination chemotherapy but are infrequently cured. The major innovation in the past decade has been the introduction of targeted therapies, in particular directed to the PD1/PD‐L1 interface, which have shown substantial activity in first‐line and salvage treatment of early‐stage and metastatic disease, but with a new spectrum of side effects.

show abstract

European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update

Cited by 675 publications

References 203 publications

EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees

EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees

Thermo Reversible Hydrogel Based Delivery of Mitomycin C (UGN-101) for Treatment of Upper Tract Urothelial Carcinoma (UTUC)

Urothelial Cancer

Contact Info

Product

Resources

About